The GLORY-1 phase 3 trial provides the most reliable data on what to expect from mazdutide. At 48 weeks, mean weight loss was 14.4% from baseline at the 6 mg dose, with full completers reaching about 18%. That’s roughly between semaglutide (STEP 1: 14.9% at 68 weeks) and tirzepatide (SURMOUNT-1: 20.9% at 72 weeks).<\/p>\n
The trajectory is what most patients want to know. Weight doesn’t come off in a straight line, and the early weeks look different from the middle and late phases of treatment. Knowing the pattern in advance reduces the discouragement that comes from comparing yourself to the average at the wrong checkpoint.<\/p>\n
This article walks through the realistic timeline week by week, what plateaus look like, what the trial data shows about non-responders, and how mazdutide compares to other GLP-1 options on the market today.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The typical pattern is small loss in the first month, accelerating loss from months 2 through 8, then gradual slowing as the body approaches its new set point.<\/strong> Specific numbers from GLORY-1: 2 to 4% at week 4, 7 to 9% at week 12, 13 to 15% at week 24, and 16 to 18% at week 48 for the 6 mg group.<\/p>\n Quick Answer: GLORY-1 (Ji et al. 2025 NEJM) showed 14.4% mean weight loss at week 48 on 6 mg, with completers averaging ~18%<\/p>\n The first month is mostly tolerance building at 1.5 mg. Weight changes are small and often confused with normal water weight fluctuations. Many patients lose 2 to 5 pounds total in the starter dose phase.<\/p>\n The middle phase (weeks 5 to 24) is where most loss happens. Patients are stepping up through 3 mg, 4.5 mg, and 6 mg, with appetite suppression strong throughout. Loss of 1 to 2 pounds per week is common in this phase.<\/p>\n The later phase (weeks 24 to 48) shows slower but continued loss. The body adapts to lower calorie intake, and the rate slows to about 0.5 pound per week or less. Many patients reach their personal floor around month 9 to 12.<\/p>\n Weeks 1 to 4 are the 1.5 mg starter dose phase.<\/strong> Most patients lose 2 to 5 pounds during this month, mostly from reduced appetite and some water weight shifts. The drug is doing more for tolerance than for fat loss at this stage.<\/p>\n Many patients are disappointed by the slow start. It’s a common reason for early discontinuation if expectations weren’t set well. The lower dose is designed to build GI tolerance, not to drive weight loss. Patients who push through and reach the 3 mg step almost always see a clear acceleration in weeks 5 to 8.<\/p>\n What patients report in this phase: mild nausea after the first one to two injections, noticeable but not dramatic appetite reduction, smaller portion sizes at meals, less interest in snacking. Some patients report better blood sugar readings if they’re tracking glucose for diabetes or insulin resistance.<\/p>\n The 3 mg and 4.5 mg phases are where mazdutide starts delivering visible results.<\/strong> Most patients lose 5 to 10% of starting body weight by week 12, which for a 200 pound person is 10 to 20 pounds.<\/p>\n The pace picks up because appetite suppression deepens with the higher dose. Patients report eating roughly half what they used to eat, with no conscious effort. Food cravings often disappear or become much weaker. Many people lose interest in foods they previously couldn’t resist, like sweets or processed snacks.<\/p>\n This is also the phase where most patients first see clothing fitting differently. Pants that were tight feel loose. Belts move in a notch. Friends and family start noticing. The visible change is reinforcing and helps build long-term commitment to the medication.<\/p>\n The 6 mg maintenance phase, started around week 13, is where the bulk of weight loss happens.<\/strong> By week 24, GLORY-1 participants on 6 mg averaged around 14% loss from baseline.<\/p>\n The rate slows compared to the acceleration phase but remains steady. Patients lose roughly 0.5 to 1 pound per week throughout this phase. Some weeks show no change; others show three or four pound drops. The average smooths out to a steady decline.<\/p>\n What patients report in this phase: stable energy levels (often better than before), continued reduced appetite without feeling deprived, more comfortable physical activity, improvements in joint pain and sleep quality, lower blood pressure, and (for those with diabetes) significantly lower HbA1c.<\/p>\n The late phase brings the body close to its new set point.<\/strong> Weight loss slows to maybe a quarter pound per week or less. GLORY-1 completers averaged around 18% loss at week 48, but the curve was clearly flattening by month nine.<\/p>\n Plateaus typically show up around months 6 to 8. The scale stops moving for two to four weeks at a time, then resumes. This is the body’s metabolic adaptation: as you weigh less, you burn fewer calories at rest, and the calorie deficit shrinks even if intake stays the same.<\/p>\n Most plateaus break with patience. Some patients add small interventions: increasing protein intake, adding resistance training, getting better sleep, or temporarily reducing carbohydrate intake. These are lifestyle adjustments, not dose changes. The 6 mg dose is the approved maximum.<\/p>\n Key Takeaway: About 80% of GLORY-1 participants on 6 mg lost at least 5% of body weight; 60% lost at least 10%<\/p>\n In GLORY-1 at the 6 mg dose, roughly 80% of participants lost at least 5% of body weight by week 48.<\/strong> About 60% lost at least 10%. Around 30% lost more than 15%. The non-responder group (less than 5% loss) was small but real, at around 15 to 20%.<\/p>\n For comparison, STEP 1 semaglutide had 86% reach 5%, 69% reach 10%, and 50% reach 15%. SURMOUNT-1 tirzepatide had 91% reach 5%, 83% reach 10%, and 56% reach 20%. Mazdutide sits in roughly the same range, with response rates that compete with semaglutide and approach tirzepatide.<\/p>\n Non-response is partly genetic and partly behavioral. Patients who eat through fullness signals, drink high-calorie beverages, or have undiagnosed conditions (like hypothyroidism) tend to respond less. Some patients simply don’t have the typical biological response to GLP-1 activation.<\/p>\n At 6 months on mazdutide 6 mg, most patients have lost 12 to 16% of starting body weight.<\/strong> At 12 months, most are at 15 to 20%. The 6 month mark captures the steepest part of the loss curve; the 12 month mark captures the maintenance settling.<\/p>\n For a starting weight of 200 pounds, expect roughly 25 to 32 pounds gone at 6 months and 30 to 40 pounds gone at 12 months. These are averages. Some patients lose more, some less. Patients with more weight to lose tend to see larger absolute drops; patients closer to their goal weight see smaller drops.<\/p>\n The first six months are mostly fat loss with some lean tissue loss. The second six months are increasingly fat loss as the body protects lean mass. Maintaining protein intake and adding resistance training preserve muscle through both phases.<\/p>\n Trial data suggests mazdutide produces similar or slightly less weight loss than tirzepatide and slightly more than semaglutide, though no head-to-head trials have been done.<\/strong> Real-world results match this rough ordering.<\/p>\n STEP 1 semaglutide: 14.9% at 68 weeks SURMOUNT-1 tirzepatide: 20.9% at 72 weeks GLORY-1 mazdutide: ~18% at 48 weeks completers<\/p>\n The mazdutide advantage may be the glucagon mechanism, which adds energy expenditure on top of appetite suppression. This could mean less metabolic adaptation as weight drops, though long-term data isn’t out yet to confirm.<\/p>\n If you’re looking for available GLP-1 options today, semaglutide and tirzepatide are accessible through TrimRx with a free assessment quiz. Mazdutide isn’t yet FDA-approved.<\/p>\n Weight regain is the rule, not the exception, when GLP-1 drugs are stopped.<\/strong> STEP 4 showed semaglutide patients regained about two-thirds of lost weight within a year of stopping. Mazdutide hasn’t had a comparable withdrawal trial published, but the mechanism is similar and the same pattern should be expected.<\/p>\n Some weight stability after stopping is possible with strong lifestyle support: protein-heavy diet, regular resistance training, adequate sleep, low alcohol intake. But the typical pattern is gradual regain over 6 to 18 months back toward baseline.<\/p>\n This is why mazdutide is positioned as a chronic medication, like blood pressure or cholesterol drugs. The disease (obesity) doesn’t go away with weight loss; the drug suppresses it. Stopping the drug means the disease comes back. Some patients hate this framing, others find it clarifying.<\/p>\n Bottom line: Stopping the medication typically leads to weight regain similar to what STEP 4 showed for semaglutide<\/p>\n Visible results usually start around week 6 to 8 once you’re at 3 mg or higher. Clothing fit changes typically show up at week 10 to 14. Friends and family notice around week 12 to 16.<\/p>\n Week 1 is too early to see meaningful change. The 1.5 mg starter dose is a tolerance phase. Real loss accelerates once you reach 3 mg in week 5.<\/p>\n No. Most patients reach a new set point between months 9 and 14 and stop losing. This is normal and expected.<\/p>\n Plateaus around month 6 are very common. Most break on their own within two to four weeks. Resistance training, protein intake, and sleep all help.<\/p>\n The majority is fat. Some lean mass is lost (around 20 to 25% of total weight lost), which is typical of any weight loss. Resistance training and adequate protein minimize lean loss.<\/p>\n Yes, on average. Body fat percentage drops more than total weight, since lean mass is preserved better than fat mass with proper training and protein intake.<\/p>\n No. Skipping titration steps doesn’t speed weight loss but dramatically increases side effects. Most patients who try this end up discontinuing the drug entirely.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The GLORY-1 phase 3 trial provides the most reliable data on what to expect from mazdutide.<\/p>\n","protected":false},"author":11,"featured_media":90186,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Mazdutide Real Results: Weight Loss Timeline & What Patients Report","_yoast_wpseo_metadesc":"The GLORY-1 phase 3 trial provides the most reliable data on what to expect from mazdutide.","_yoast_wpseo_focuskw":"mazdutide results timeline","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-90187","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90187"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90187\/revisions"}],"predecessor-version":[{"id":92454,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90187\/revisions\/92454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90186"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Happens in the First 4 Weeks?<\/h2>\n
Weeks 5 to 12: The Acceleration Phase<\/h2>\n
Weeks 13 to 24: The Main Loss Phase<\/h2>\n
Weeks 25 to 48: The Late Phase and Plateau<\/h2>\n
What Percentage of People Are Responders?<\/h2>\n
What Weight Loss Should You Expect at 6 Months Versus 12 Months?<\/h2>\n
How Does Mazdutide Compare to Other GLP-1 Drugs in Real-world Results?<\/h2>\n
What Happens When You Stop Mazdutide?<\/h2>\n
FAQ<\/h2>\n
When Will I See Results?<\/h3>\n
Why Isn’t the Scale Moving in Week 1?<\/h3>\n
Will I Keep Losing Weight Indefinitely?<\/h3>\n
What If I Plateau for a Month?<\/h3>\n
Is the Weight Loss Mostly Fat?<\/h3>\n
Will My Body Composition Improve?<\/h3>\n
Can I Lose Weight Faster by Skipping Titration?<\/h3>\n